Analysts’ Top Services Picks: OncoSec Medical (ONCS), Pareteum Corp (TEUM)

By Jason Carr

There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on OncoSec Medical (ONCSResearch Report) and Pareteum Corp (TEUMResearch Report) with bullish sentiments.

OncoSec Medical (ONCS)

Maxim Group analyst Jason McCarthy maintained a Buy rating on OncoSec Medical yesterday and set a price target of $10. The company’s shares closed yesterday at $2.53, close to its 52-week low of $2.30.

McCarthy commented:

“OncoSec announced a collaboration agreement with Dana-Farber Cancer Institute whereby OncoSec acquired an exclusive option to licensing rights to CAR-T candidates and associated IP from research being conducted the Marasco Laboratory.”

According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -18.6% and a 24.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OncoSec Medical with a $10 average price target.

See today’s analyst top recommended stocks >>

Pareteum Corp (TEUM)

In a report released yesterday, Allen Klee from Maxim Group reiterated a Buy rating on Pareteum Corp, with a price target of $9. The company’s shares closed yesterday at $2.61.

Klee wrote:

“Marketing with management reinforces our positive outlook and confidence in our 2019 earnings forecast.”

According to TipRanks.com, Klee has 0 stars on 0-5 star ranking scale with an average return of -16.7% and a 27.7% success rate. Klee covers the Technology sector, focusing on stocks such as Sify Technologies Limited, Dolphin Entertainment Inc, and ATN International Inc.

Currently, the analyst consensus on Pareteum Corp is a Strong Buy with an average price target of $8, a 206.5% upside from current levels. In a report issued on June 18, Northland Securities also assigned a Buy rating to the stock with a $8.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.